While following all the menin updates since their preclinical development we’ve gone in short order from “do they work?” to “which one, for whom, and in what combinations?” in a pretty short timeline.

The calm before the storm at Orlando, FL

While Wall St loves a ‘winner takes all’ battle, emerging evidence suggests this is going to be a more fragmented market with room for several players to shine, although some may do less well than expected.

It turns out clinical data presented at ASH 2025 may separate contenders from pretenders.

In our latest update, we explore the evidence for success with combinatorial therapy and indicate which way the tea leaves are looking so far since there are some surprises in the mix…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers